Skip to main content
Clinical Trials/NCT00458978
NCT00458978CompletedPhase 2

Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients

National Cancer Institute (NCI)1 site in 1 country6 target enrollmentStarted: February 2007Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
6
Locations
1
Primary Endpoint
Tumor response (complete response [CR], partial response [PR], progressive disease [PD], and stable disease [SD]) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria

Study Overview

Brief Summary

This phase II trial is studying how well cediranib maleate works in treating patients with recurrent or newly diagnosed metastatic head and neck cancer. Cediranib maleate may stop the growth of head and neck cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the objective clinical response in patients with recurrent or newly diagnosed metastatic squamous cell carcinoma of the head and neck treated with AZD2171 (cediranib maleate).

SECONDARY OBJECTIVES:

I. Determine the safety profile of this drug in these patients. II. Assess the early and late physiological and biological effects of this drug on tumor interstitial fluid pressure, pO2, and tumor microvasculature.

III. Assess the value of potential noninvasive biomarkers of response, including plasma levels of molecules involved in angiogenesis, circulating endothelial cells and progenitor cells, and functional imaging changes before and after treatment.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically confirmed squamous cell carcinoma of the head and neck meeting one of the following criteria:
  • Recurrent disease
  • Previously treated with standard curative therapy, including surgery and/or radiotherapy with or without chemotherapy
  • Newly diagnosed metastatic disease
  • Must be deemed incurable by all of the following:
  • Salvage surgery
  • Radiotherapy
  • Measurable disease ≥ 1 cm by conventional techniques, flexible fiberoptic laryngoscopy, or examination under anesthesia
  • No more than 2 prior conventional or investigational systemic therapies for categorically incurable local-regional or distant disease
  • No known primary brain tumor or brain metastases
  • ECOG performance status 0-1
  • Life expectancy ≥ 6 months
  • WBC > 3,000/mm³
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • Hemoglobin > 8 g/dL
  • Bilirubin normal
  • AST and ALT ≤ 2.5 times upper limit of normal
  • Creatinine normal OR creatinine clearance > 60 mL/min
  • Proteinuria ≤ +1 on 2 consecutive urine dipsticks taken ≥ 1 week apart
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • History of nonmelanoma skin cancer or other prior malignancy allowed provided the cancer has been in remission for > 3 years
  • No history of allergic reaction attributed to compounds of similar chemical or biological composition to AZD2171
  • No hypertension (i.e., systolic blood pressure (BP) > 160 mm Hg and diastolic BP > 100 mm Hg)
  • No history of hypertensive urgency, hypertensive emergency, or end-organ damage (i.e., thrombotic stroke, transient ischemic attacks, intracerebral hemorrhage, myocardial infarction, aortic aneurysm, or aortic dissection)
  • QTc ≤ 500 msec (with Bazett's correction)
  • No history of familial long QT syndrome
  • No concurrent uncontrolled illness including, but not limited to, any of the following:
  • Bleeding diathesis
  • Congestive heart failure, defined as New York Heart Association (NYHA) class III-IV congestive heart failure
  • NYHA class II congestive heart failure allowed provided there is increased monitoring
  • Significant ECG abnormality
  • Peripheral vascular disease
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • Pulmonary edema
  • Atrioventricular (AV) conduction abnormalities
  • Sick sinus syndrome
  • Second- or third-degree AV block
  • Deep venous thrombosis
  • No nonhealing ulcers, bone fracture, or wounds
  • No psychiatric illness or social situation that would preclude study compliance
  • No traumatic injury within the past 7 days
  • No known coagulopathy that increases risk of bleeding
  • No history of clinically significant hemorrhages
  • See Disease Characteristics
  • Recovered from all prior therapies
  • No prior antiangiogenic therapy
  • +9 more not shown

Exclusion Criteria

  • Not provided

Arms & Interventions

Treatment (enzyme inhibitor)

Experimental

Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention: Cediranib Maleate (Drug)

Treatment (enzyme inhibitor)

Experimental

Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention: Laboratory Biomarker Analysis (Other)

Outcomes

Primary Outcomes

Tumor response (complete response [CR], partial response [PR], progressive disease [PD], and stable disease [SD]) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria

Time Frame: Baseline to day 29

Compared using logistic regression.

Secondary Outcomes

  • Adverse events, graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0(Up to 28 days after last dose of study treatment)
  • Distant metastasis(Every 2 courses until progression)
  • Overall survival(Up to 28 days after last dose of study treatment)
  • Progression-free survival(Up to 28 days after last dose of study treatment)

Investigators

Sponsor Class
Nih
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesUntreated Adult Acute Myeloid Leukemia
NCT00475150National Cancer Institute (NCI)39
Completed
Phase 2
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube CancerRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
NCT00278343National Cancer Institute (NCI)74
Completed
Phase 2
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
NCT00227760National Cancer Institute (NCI)44
Completed
Phase 2
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By SurgeryAdvanced Malignant MesotheliomaEpithelial MesotheliomaLocalized Malignant MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
NCT00309946National Cancer Institute (NCI)51
Completed
Phase 2
AZD2171 in Treating Patients With Recurrent Small Cell Lung CancerRecurrent Non-small Cell Lung Cancer
NCT00245063National Cancer Institute (NCI)25